• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A phase-2 study of pembrolizumab in patients with biologically selected subtypes of relapsed/refractory aggressive lymphomas.

作者信息

Merrill Mwanasha H, Redd Robert A, Fisher David C, Abramson Jeremy S, Barnes Jeffrey, Choi Jaehyuk, Jacobson Caron A, Kim Austin I, Lunning Matthew A, Jester Hallie D, Jeter Erin L, McDonough Mikaela M, Armand Philippe, Jacobsen Eric D

机构信息

Department of Hematology-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Massachusetts General Hospital, Boston, MA, USA.

出版信息

Leuk Lymphoma. 2025 Jul;66(7):1354-1357. doi: 10.1080/10428194.2025.2478525. Epub 2025 Mar 25.

DOI:10.1080/10428194.2025.2478525
PMID:40134121
Abstract
摘要

相似文献

1
A phase-2 study of pembrolizumab in patients with biologically selected subtypes of relapsed/refractory aggressive lymphomas.帕博利珠单抗治疗复发/难治性侵袭性淋巴瘤生物学选择亚型患者的2期研究。
Leuk Lymphoma. 2025 Jul;66(7):1354-1357. doi: 10.1080/10428194.2025.2478525. Epub 2025 Mar 25.
2
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: a post hoc analysis of KEYNOTE-204 by prior lines of therapy.帕博利珠单抗治疗复发或难治性霍奇金淋巴瘤：基于先前治疗线数的KEYNOTE-204事后分析
Leuk Lymphoma. 2025 Sep;66(9):1710-1719. doi: 10.1080/10428194.2025.2502805. Epub 2025 Jun 23.
3
Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial.皮下注射博纳吐单抗治疗复发或难治性B细胞急性淋巴细胞白血病成人患者：一项多中心、单臂、1/2期试验的事后安全性和活性分析
Lancet Haematol. 2025 Jun 13. doi: 10.1016/S2352-3026(25)00144-9.
4
PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes.
Eur Urol Oncol. 2025 Aug;8(4):1059-1069. doi: 10.1016/j.euo.2025.04.025. Epub 2025 Jun 25.
5
A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies.一项关于白细胞介素-15联合莫格利珠单抗治疗复发难治性T细胞恶性肿瘤的1期研究。
Blood Neoplasia. 2024 Nov 2;2(1):100054. doi: 10.1016/j.bneo.2024.100054. eCollection 2025 Feb.
6
Highly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review.复发或难治性外周T细胞淋巴瘤挽救治疗方案的高度多样化疗效：一项系统评价
PLoS One. 2016 Oct 6;11(10):e0161811. doi: 10.1371/journal.pone.0161811. eCollection 2016.
7
Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer.一项针对复发或顺铂难治性睾丸癌患者的紫杉醇I/II期试验的初步结果。
J Cancer Res Clin Oncol. 1994;120(12):754-7. doi: 10.1007/BF01194278.
8
A systematic overview of radiation therapy effects in non-Hodgkin's lymphoma.非霍奇金淋巴瘤放射治疗效果的系统综述。
Acta Oncol. 2003;42(5-6):605-19. doi: 10.1080/02841860310014435.
9
Evaluating mogamulizumab in the treatment of primary cutaneous T-cell lymphoma.评估莫加莫拉单抗治疗原发性皮肤T细胞淋巴瘤的疗效。
Immunotherapy. 2025 Jun;17(8):551-559. doi: 10.1080/1750743X.2025.2520153. Epub 2025 Jun 24.
10
Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphomas as Front-Line Consolidation or in the Relapsed/Refractory Setting: A Systematic Review/Meta-Analysis.高剂量疗法及自体造血细胞移植用于外周T细胞淋巴瘤一线巩固治疗或复发/难治性病例的疗效：一项系统评价/荟萃分析
Biol Blood Marrow Transplant. 2016 May;22(5):802-14. doi: 10.1016/j.bbmt.2015.12.004. Epub 2015 Dec 20.

引用本文的文献

1
Histiocytic Sarcoma: A Review and Update.组织细胞肉瘤：综述与更新
Int J Mol Sci. 2025 Sep 3;26(17):8554. doi: 10.3390/ijms26178554.